A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by activating the mother’s body’s defences to produce protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85% protection when immunised 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from day one
- Protection possible with two-week gap before early delivery
- Vaccination during the third trimester still provides meaningful infant protection
Strong evidence from the latest research
The effectiveness of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study conducted across England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s practical effectiveness. The study’s results have been supported by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across diverse populations and circumstances.
The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This clear distinction emphasises the vaccine’s critical role in preventing serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection rates and hospitalisations. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically significant and representative of the broader population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology measured real-world outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine performs when delivered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the risks
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it extremely challenging for affected infants to breathe and feed adequately. Parents frequently observe their babies fighting for breath, their chests heaving as they work to get adequate oxygen into their weakened respiratory system. Whilst the majority of babies recover with palliative treatment, a modest yet notable number die from respiratory syncytial virus complications annually, making immunisation programmes a vital health service objective for safeguarding the youngest and most vulnerable individuals in the population.
- RSV produces lung inflammation, leading to serious respiratory problems in babies
- Half of all newborns catch the infection during their first few months alive
- Symptoms span from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK infants require serious hospital care for RSV annually
- A small number of infants die from RSV related complications each year in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have stressed the value of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that the timing is essential for ensuring newborns benefit from the maximum immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies via the placenta.
The messaging from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These geographical variations reflect variations in medical facilities, engagement approaches, and community involvement initiatives, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to connect with expectant mothers
- Geographic variations in vaccination coverage levels throughout England necessitate strategic intervention
- Community health services tailoring initiatives to align with community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness provides concrete gains for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this preventative solution, the 80% reduction in admissions represents thousands of infants shielded from serious illness. Parents no more face the upsetting situation of watching their newborns struggle for breath or difficulty feeding, symptoms that define serious RSV disease. The vaccine has markedly changed the terrain of neonatal respiratory health, offering expectant mothers a preventative option to shield their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection led to profound brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab emphasises the transformative consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women in their late pregnancy, changing what was once an unavoidable seasonal threat into a manageable risk.